Compare Cassava Sciences Inc (FLNA) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.475, up 0.03% on the day. Technical indicators show a bearish bias with moving averages signaling sell pressure, while oscillators like the 6-day relative strength index at 15.33 suggest oversold conditions. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes. The ETF focuses on short-duration TIPS to minimize interest rate risk, with institutional buying noted in recent SEC filings.

The outlook for VTIP is cautiously positive as a defensive inflation hedge, with real yields at multi-decade highs boosting appeal. However, risks include persistent inflation above the Fed's target and potential volatility from rate uncertainty. Investors seeking low-cost, short-duration inflation protection may find value, but the bearish technical trend warrants monitoring for stability.